4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

The present document has been conceived as the European update to the American
College of Cardiology (ACC)/American Heart Association (AHA)/ESC 2006 Guidelines for …

Brugada syndrome is an inherited heart disease without structural abnormalities that is
thought to arise as a result of accelerated inactivation of Na channels and predominance of …

Supraventricular arrhythmias are common and patients are often symptomatic, requiring
management with drugs and electrophysiological procedures. The ESC published …

Background: The entirely subcutaneous implantable cardioverter-defibrillator (S-ICD) is the
first implantable defibrillator that avoids placing electrodes in or around the heart. Two large …

Aims The totally subcutaneous implantable-defibrillator (S-ICD) is a new alternative to the
conventional transvenous ICD system to minimize intravascular lead complications. There …

Background The subcutaneous implantable cardioverter–defibrillator (ICD) was designed to
avoid complications related to the transvenous ICD lead by using an entirely extrathoracic …

Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was
developed to defibrillate ventricular arrhythmias, avoiding drawbacks of transvenous leads …

The 'Lambeth Conventions' is a guidance document, written in 1987 (Walker et al., 1988),
intended to be of practical value in the investigation of experimental arrhythmias induced by …

Background: The subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and
effective for sudden cardiac death prevention. However, patients in previous S-ICD studies …